Risankizumab Effective Against Refractory Psoriatic Arthritis

The IL-23 inhibitor provides some relief for patients with active psoriatic arthritis whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase 3 trial.
Reuters Health Information

source https://www.medscape.com/viewarticle/966708?src=rss